Literature DB >> 11831503

Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles.

Steven Shoptaw1, Cathy J Reback, Thomas E Freese.   

Abstract

Methamphetamine, a drug used at alarming rates among gay/bisexual males in the West, is often combined with sexual activities, thereby increasing HIV-related risks in an already high-risk group. Findings from 68 gay/bisexual men seeking treatment for methamphetamine dependence in Hollywood, California were analyzed to predict HIV serostatus based on demographic, drug use, or sexual behavior variables. Results showed that more HIV-infected participants than non-infected men reported medical problems (97.6% versus 46.2%; X2 = 24.7, df = 1, p < .0001), histories of genital gonorrhea (59.5% versus 26.9%; X2 = 6.9, df = 1, p < .01), use of injection methods (45.2% versus 19.2%; X2 = 4.8, df = 1, p < .03), and more sexual partners with unprotected receptive anal intercourse in the 30 days prior to intake (5.9 versus 0.7; separate t = 3.5, df = 43.7, p < .001). More non-infected participants (19.2%) reported suicidal thoughts than HIV-infected men (0%; X2 = 4.8, df = 1, p < .03). Discriminant function analysis correctly classified 74.6% of cases into serostatus groupings based on presence of suicidal thoughts, history of gonorrhea, number of sexual partners with unprotected receptive anal intercourse and prior methamphetamine treatment. Findings provide information that may prove helpful in tailoring culturally relevant treatment and prevention messages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11831503     DOI: 10.1300/j069v21n01_08

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  31 in total

Review 1.  A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine.

Authors:  Radha Rajasingham; Matthew J Mimiaga; Jaclyn M White; Megan M Pinkston; Rachel P Baden; Jennifer A Mitty
Journal:  AIDS Patient Care STDS       Date:  2011-11-09       Impact factor: 5.078

2.  Breaking the bond between stimulant use and risky sex: a qualitative study.

Authors:  Thomas Lyons; Gopika Chandra; Jerome Goldstein; David G Ostrow
Journal:  Subst Abus       Date:  2010-10       Impact factor: 3.716

Review 3.  The impact of medication regimen factors on adherence to chronic treatment: a review of literature.

Authors:  Karen S Ingersoll; Jessye Cohen
Journal:  J Behav Med       Date:  2008-01-19

4.  Predictors of methamphetamine injection in out-of-treatment IDUs.

Authors:  Karen F Corsi; Carol F Kwiatkowski; Robert E Booth
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

Review 5.  Interventions to Reduce Drug Use Among Methamphetamine Users at Risk for HIV.

Authors:  Karen F Corsi; Steve Shoptaw; Musheng Alishahi; Robert E Booth
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

6.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

7.  Pride, Shame, and the Trouble with Trying to Be Normal.

Authors:  Theodore K Gideonse
Journal:  Ethos       Date:  2015-12-02

8.  Recruiting hard-to-reach drug-using men who have sex with men into an intervention study: lessons learned and implications for applied research.

Authors:  Christian Grov; Donald Bux; Jeffrey T Parsons; Jon Morgenstern
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

9.  Methamphetamine enhances HIV infection of macrophages.

Authors:  Hao Liang; Xu Wang; Hui Chen; Li Song; Li Ye; Shi-Hong Wang; Yan-Jian Wang; Lin Zhou; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

10.  Prediction of HIV acquisition among men who have sex with men.

Authors:  Timothy W Menza; James P Hughes; Connie L Celum; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.